Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Karolina, Hankiewicz"'
Publikováno v:
eNeurologicalSci, Vol 33, Iss , Pp 100479- (2023)
Externí odkaz:
https://doaj.org/article/a27af6e036254c1fa67a37dd2d88fedb
Autor:
Camille Sabathé, Romain Casey, Sandra Vukusic, Emmanuelle Leray, Guillaume Mathey, Jérôme De Sèze, Jonathan Ciron, Sandrine Wiertlewski, Aurélie Ruet, Jean Pelletier, Hélène Zéphir, Laure Michel, Christine Lebrun-Frenay, Xavier Moisset, Eric Thouvenot, Jean-Philippe Camdessanché, Serge Bakchine, Bruno Stankoff, Abdullatif Al Khedr, Philippe Cabre, Elisabeth Maillart, Eric Berger, Olivier Heinzlef, Karolina Hankiewicz, Thibault Moreau, Olivier Gout, Bertrand Bourre, Abir Wahab, Pierre Labauge, Alexis Montcuquet, Gilles Defer, Aude Maurousset, Nicolas Maubeuge, Dalia Dimitri Boulos, Haïfa Ben Nasr, Chantal Nifle, Olivier Casez, David-Axel Laplaud, Yohann Foucher
Publikováno v:
Multiple Sclerosis Journal
Multiple Sclerosis Journal, 2023, 29 (2), pp.236-247. ⟨10.1177/13524585221139156⟩
Multiple Sclerosis Journal, 2023, 29 (2), pp.236-247. ⟨10.1177/13524585221139156⟩
Background: In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression. Objective: We aimed to develop and validate a dynamic score to guide the early decision to switch from fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb0d295f009630c7a4453984a4cacd15
https://amu.hal.science/hal-04086418
https://amu.hal.science/hal-04086418
Autor:
Xavier Moisset, Bruno Stankoff, Pierre Clavelou, Karolina Hankiewicz, Bruno Brochet, Olivier Casez, Bruno Pereira, Chantal Nifle, Thibault Moreau, Sandra Vukusic, Christine Lebrun-Frenay, Eric Thouvenot, Alain Créange, Olivier Gout, Corinne Pottier, Olivier Heinzlef, Caroline Papeix, Gilles Defer, Eric Berger, David Laplaud, Audrey-Anne Fouchard, S. Bakchine, Alexis Montcuquet, Jean Pelletier, Jérôme De Seze, Dalia Dimitri Boulos, Jean-Philippe Camdessanché, Pierre Labauge, Bertrand Bourre, Philippe Cabre, Abdullatif Al-Khedr, Aude Maurousset, Frederic Taithe, Gilles Edan, Jonathan Ciron, Nicolas Maubeuge, Guillaume Mathey, Patrick Vermersch
Publikováno v:
European Journal of Neurology
European Journal of Neurology, 2021, 28 (6), pp.2026-2036. ⟨10.1111/ene.14790⟩
European Journal of Neurology, Wiley, 2021, 28 (6), pp.2026-2036. ⟨10.1111/ene.14790⟩
European Journal of Neurology, 2021, 28 (6), pp.2026-2036. ⟨10.1111/ene.14790⟩
European Journal of Neurology, Wiley, 2021, 28 (6), pp.2026-2036. ⟨10.1111/ene.14790⟩
International audience; Background and purpose: Disease-modifying therapies (DMTs) have an impact on relapses and disease progression. Nonetheless, many patients with multiple sclerosis (MS) remain untreated. The objectives of the present study were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c7aef750070852e10487d85e1fd5181
https://doi.org/10.1111/ene.14790
https://doi.org/10.1111/ene.14790
Autor:
Elodie Meppiel, Nathan Peiffer-Smadja, Alexandra Maury, Imen Bekri, Cécile Delorme, Virginie Desestret, Lucas Gorza, Geoffroy Hautecloque-Raysz, Sophie Landre, Annie Lannuzel, Solène Moulin, Peggy Perrin, Paul Petitgas, François SellaI, Adrien Wang, Pierre Tattevin, Thomas de Broucker, Sophie Abgrall, Fanny Alby-Laurent, Thibault Allou, Joséphine Amevigbe, Hanifa Amarguellay, Nabil Alloussi, Guillaume Baille, Mathilde Barbaz, Lamia Bencherif, Samia Bensaadi, Guillaume Beraud, Alexandra Bizot, Laure Bottin, Fabrice Bruneel, Jean-Philippe Camdessanche, Jeanne Chauffier, Jean-Philippe Csajaghy, Chloé De Broucker, Thomas De Broucker, Luc Defebvre, Elodie Dembloque, Nathalie Derache, Olivier Dereeper, Céline Derollez, Cécile Descotes-Genon, Mathilde Devaux, Lydie Dubuc, Gilles Edan, Andréa Fickl, Thibault Fraisse, Michel Gugenheim, Karolina Hankiewicz, Yves Hansmann, Carole Henry, Stéphanie Jobard, Fanny Jouan, Arnaud Kwiatkowski, Thibault Lalu, Johan Leguilloux, Camille Lejeune, Clémence Liegeois, Sophie Mahy, Jonathan Marey, Laure Michel, Rita Mitri, Chloé Moulin, Asma Omarjee, Canan Ozsancak, Fernando Pico, Marie Poupard, Valérie Rabier, Camille Rizzato, Caroline Roos, Julien Saison, Naomi Sayre, Nicolas Sedillot, François Sellal, Jérôme Servan, Caroline Storey, Laurent Suchet, Paul Tarteret, Mathilde Thiebaut, Claudia Vaduva, David Varlan, Virginie Zarrouk
Publikováno v:
Clinical Microbiology and Infection
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2020, ⟨10.1016/j.cmi.2020.11.005⟩
Clinical Microbiology and Infection, 2020, ⟨10.1016/j.cmi.2020.11.005⟩
Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2020, ⟨10.1016/j.cmi.2020.11.005⟩
Clinical Microbiology and Infection, 2020, ⟨10.1016/j.cmi.2020.11.005⟩
International audience; OBJECTIVES: To provide an overview of the spectrum, characteristics and outcomes of neurologic manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. METHODS: We conducted a sing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::755a79dc94a42ef2a920c4b9fc507544
https://doi.org/10.1016/j.cmi.2020.11.005
https://doi.org/10.1016/j.cmi.2020.11.005
Autor:
Fabien Rollot, Justine Couturier, Romain Casey, Sandrine Wiertlewski, Marc Debouverie, Jean Pelletier, Jérôme De Sèze, Pierre Labauge, Aurélie Ruet, Eric Thouvenot, Jonathan Ciron, Eric Berger, Olivier Gout, Pierre Clavelou, Bruno Stankoff, Olivier Casez, Bertrand Bourre, Hélène Zephir, Thibault Moreau, Christine Lebrun-Frenay, Elisabeth Maillart, Gilles Edan, Jean-Philippe Neau, Alexis Montcuquet, Philippe Cabre, Jean-Philippe Camdessanché, Gilles Defer, Haifa Ben Nasr, Aude Maurousset, Karolina Hankiewicz, Corinne Pottier, Emmanuelle Leray, Sandra Vukusic, David-Axel Laplaud
Publikováno v:
Neurotherapeutics
Neurotherapeutics, 2022, 19 (2), pp.476-490. ⟨10.1007/s13311-022-01202-1⟩
Neurotherapeutics : the Journal of the American Society For Experimental
Neurotherapeutics : the Journal of the American Society For Experimental, 2022, ⟨10.1007/s13311-022-01202-1⟩
Neurotherapeutics, 2022, 19 (2), pp.476-490. ⟨10.1007/s13311-022-01202-1⟩
Neurotherapeutics : the Journal of the American Society For Experimental
Neurotherapeutics : the Journal of the American Society For Experimental, 2022, ⟨10.1007/s13311-022-01202-1⟩
In France, two therapeutic strategies can be offered after fingolimod (FNG) withdrawal to highly active relapsing–remitting multiple sclerosis (RRMS) patients: natalizumab (NTZ) or anti-CD20. We compared the effectiveness of these two strategies as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f52d6c446c6fcb69dd04da9f2f5743e3
https://hal.science/hal-03594074
https://hal.science/hal-03594074
Autor:
Géraud, Forestier, Simon, Escalard, Jacques, Sedat, Suzana, Saleme, Charbel, Mounayer, Alexis, Montcuquet, Stanislas, Smajda, Marie, Cantier, Charles, Gregoire, Karolina, Hankiewicz, Yves, Chau, Laurent, Suissa, Jérôme, Berge, Frédéric, Clarençon, Aymeric, Rouchaud, Eimad, Shotar
Publikováno v:
Neuroradiology. 64(5)
To report the occurrence of non-ischemic cerebral enhancing (NICE) lesions following mechanical thrombectomy (MT) through the retrospective French nationwide registry of NICE lesions. All thrombectomy capable stroke centers (TSC) in France were invit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dbad3ee2da302a495537eac5260210aa
https://pubmed.ncbi.nlm.nih.gov/35199209
https://pubmed.ncbi.nlm.nih.gov/35199209
Autor:
Alexis Montcuquet, Henrik Kahr Mathiesen, Tomas Kalincik, Marc Girard, Karolina Hankiewicz, Marco Onofrj, Francois Grand Maison, Raed Alroughani, Mathilde Lefort, Olivier Gout, Jeannette Lechner-Scott, Marc Debouverie, Julie Prevost, Eva Havrdova, Olivier Casez, Per Soelberg Sørensen, Pierre Duquette, Jean Pelletier, Claudio Solaro, Alessandra Lugaresi, Francesco Patti, Emmanuelle Leray, Johanna Balslev Andersen, Bassem Yamout, Céline Labeyrie, Karen Schreiber, Eric Thouvenot, Nils Koch-Henriksen, Michael Broksgaard Jensen, Elisabeth Maillart, Chantal Nifle, Stephan Bramow, Pierre Clavelou, Bruno Stankoff, Olivier Heinzlef, Finn Sellebjerg, Abir Wahab, Mark Slee, Gilles Defer, Pierre Labauge, Melinda Magyari, Steve Vucic, Guillermo Izquierdo, Helmut Butzkueven, Peter Vestergaard Rasmussen, Bertrand Bourre, Maria Trojano, Franco Granella, Corinne Pottier, Jette L. Frederiksen, Olga Skibina, Recai Turkoglu, Ivania Patry, Pierre Grammond, Bart Van Wijmeersch, Eric Berger, Aurélie Ruet, Serkan Ozakbas, Jonathan Ciron, Tünde Csépány, Jean Philippe Camdessanche, Sandra Vukusic, Nicolas Maubeuge, David Laplaud, Cavit Boz, Christine Lebrun, Claudia C. Hilt Christensen, Patrizia Sola, Vahid Shaygannejad, Romain Casey, Murat Terzi, Philippe Cabre, Jérôme De Seze, Abdullatif Al-Khedr, Dana Horakova, Pamela A. McCombe, Daniele Spitaleri, Alexandre Prat, Gilles Edan, Hélène Zéphir, Aude Marousset, Sifat Sharmin, Diana Ferraro, Sara Eichau, Rana Karabudak, Thibault Moreau
Publikováno v:
Multiple Sclerosis and Related Disorders
Multiple Sclerosis and Related Disorders, Elsevier, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Andersen, J B, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sørensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B V, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, J D, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, D A, Butzkueven, H, Kalincik, T, Vukusic, S & Magyari, M 2021, ' The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies ', Multiple Sclerosis and Related Disorders, vol. 53, 103012 . https://doi.org/10.1016/j.msard.2021.103012
Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Multiple Sclerosis and Related Disorders, Elsevier, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Andersen, J B, Sharmin, S, Lefort, M, Koch-Henriksen, N, Sellebjerg, F, Sørensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, B V, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, J D, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, D A, Butzkueven, H, Kalincik, T, Vukusic, S & Magyari, M 2021, ' The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies ', Multiple Sclerosis and Related Disorders, vol. 53, 103012 . https://doi.org/10.1016/j.msard.2021.103012
Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2f97bab4b243371f958204f4a99d850
http://hdl.handle.net/1942/34842
http://hdl.handle.net/1942/34842
Autor:
Tomas Kalincik, Marc Girard, Corinne Pottier, Murat Terzi, Jean Pelletier, Oliver Gerlach, Julie Prevost, Dana Horakova, Francois Grand'Maison, Raed Alroughani, Guillermo Izquierdo, Francesco Patti, Federico Frascoli, Maria Trojano, Franco Granella, Pamela A. McCombe, Charles B Malpas, Recai Turkoglu, Aurélie Ruet, Jonathan Ciron, Tünde Csépány, Nicolas Maubeuge, Helmut Butzkueven, Pierre Clavelou, Tamara Castillo Trivino, Marco Onofrj, Jean Philippe Camdessanche, Pierre Labauge, Vincent Van Pesch, Pierre Grammond, Abir Wahab, Roberto Bergamaschi, Aysun Soysal, Diana Ferraro, Bertrand Bourre, Olivier Gout, Jeannette Lechner-Scott, Sara Eichau, Emmanuelle Leray, Alexis Montcuquet, Pierre Duquette, Olivier Casez, Youssef Sidhom, Patrizia Sola, Bart Van Wijmeersch, Izanne Roos, Gilles Edan, Serkan Ozakbas, David Laplaud, Sandra Vukusic, Abdullatif Al Khedr, Céline Labeyrie, Philippe Cabre, Eric Thouvenot, Céline Louapre, Romain Casey, Alessandra Lugaresi, Riadh Gouider, Alasdair Coles, Eric Berger, Ivania Patry, Gerardo Iuliano, Elisabetta Cartechini, Cavit Boz, Karolina Hankiewicz, Eva Havrdova, Eduardo Aguera-Morales, J William L Brown, Jérôme De Seze, Bruno Stankoff, Olivier Heinzlef, Gilles Defer, Alexandre Prat, Chantal Nifle, Maria José Sá, Marc Debouverie, Daniele Spitaleri, Aude Maurousset, Thibault Moreau, Christine Lebrun-Frenay, Hélène Zéphir
Publikováno v:
Multiple Sclerosis Journal
Multiple Sclerosis Journal, SAGE Publications, 2021, ⟨10.1177/1352458520981300⟩
Multiple sclerosis journal, Vol. 27, no. 12, p. 1838-1851 (2021)
Multiple Sclerosis Journal, SAGE Publications, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩
Neurology
Neurology, American Academy of Neurology, 2020, 94 (15)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Publons
Web of Science
HAL
Multiple Sclerosis Journal, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩
Neurology, 2020, 94 (15)
Multiple Sclerosis Journal, SAGE Publications, 2021, ⟨10.1177/1352458520981300⟩
Multiple sclerosis journal, Vol. 27, no. 12, p. 1838-1851 (2021)
Multiple Sclerosis Journal, SAGE Publications, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩
Neurology
Neurology, American Academy of Neurology, 2020, 94 (15)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Publons
Web of Science
HAL
Multiple Sclerosis Journal, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩
Neurology, 2020, 94 (15)
International audience; Objective: To explore the associations of patient and disease characteristics with the duration of therapeutic lag for relapses and disability progression.Background: Therapeutic lag represents the delay from initiation of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bd275779a0a2c8bfba24596975ed900
https://hdl.handle.net/11380/1251074
https://hdl.handle.net/11380/1251074
Autor:
Mark Slee, Guillermo Izquierdo, Per Soelberg Soerensen, Karen Schreiber, Alexandre Prat, Francois Grand'Maison, Maria Trojano, Franco Granella, Pierre Duquette, David Laplaud, Elisabeth Maillart, Henrik Kahr Mathiesen, Bassem Yamout, Cavit Boz, Jean Pelletier, Corinne Pottier, Jette L. Frederiksen, Claudia Christina Pfleger, Tomas Kalincik, Olivier Gout, Daniele Spitaleri, Marc Girard, Marco Onofrj, Jérôme De Seze, Helmut Butzkueven, Emmanuelle Leray, Philippe Cabre, Julie Prevost, Abullatif Al-Khedr, Aude Maurousset, Eric Berger, Sifat Sharmin, Ivania Patry, Pamela A. McCombe, Patrizia Sola, Olga Skibina, Diana Ferraro, Pierre Clavelou, Francesco Patti, Finn Sellebjerg, Niels Koch-Henriksen, Alexis Montcuquet, Recai Turkoglu, Romain Casey, Bart Van Wijmeersch, Hélène Zéphir, Pierre Grammond, Dana Horakova, Davide Maimone, Serkan Ozakbas, Céline Labeyrie, Murat Terzi, Aurélie Ruet, Steve Vucic, Jonathan Ciron, Tünde Csépány, Nicolas Maubeuge, Bruno Stankoff, Mathilde Lefort, Katherine Buzzard, Karolina Hankiewicz, Jean-Philippe Camdessanché, Raed Alroughani, Michael Broksgaard Jensen, Pierre Labauge, Olivier Casez, Peter Vestergaard Rasmussen, Bertrand Bourre, Olivier Heinzlef, Gilles Defer, Gilles Edan, Alessandra Lugaresi, Abir Wahab, Melinda Magyari, Anneke van der Walt, Eva Havrdova, Johanna Balslev Andersen, Chantal Nifle, Stephan Bramow, Marc Debouverie, Thibault Moreau, Sandra Vukusic, Christine Lebrun-Frenay, Jeannette Lechner-Scott, Eric Thouvenot
Publikováno v:
CNS Drugs
CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
Sharmin, S, Lefort, M, Andersen, J B, Leray, E, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frénay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Laplaud, D, Koch-Henriksen, N, Sellebjerg, F T, Soerensen, P S, Pfleger, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
CNS Drugs, Springer Verlag, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
Sharmin, S, Lefort, M, Andersen, J B, Leray, E, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frénay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Laplaud, D, Koch-Henriksen, N, Sellebjerg, F T, Soerensen, P S, Pfleger, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators 2021, ' Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ', CNS Drugs, vol. 35, no. 11, pp. 1217-1232 . https://doi.org/10.1007/s40263-021-00860-7
CNS Drugs, Springer Verlag, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db23efcded486e57c8c7b3dd1b8db8cf
http://hdl.handle.net/11585/853457
http://hdl.handle.net/11585/853457
Autor:
Xavier Moisset, Elisabeth Maillart, Julie Pique, Ofsep Investigators, Pierre Labauge, Bruno Stankoff, Eric Thouvenot, Bertrand Bourre, Fabien Rollot, Hélène Zéphir, Nathalie Derache, Gilles Edan, Sandra Vukusic, Audrey Rico-Lamy, Christine Lebrun-Frenay, David-Axel Laplaud, Eric Berger, Nicolas Maubeuge, Ayman Tourbah, Sandrine Wiertlewski, A.-M. Guennoc, Céline Labeyrie, Patrick Vermersch, Olivier Heinzlef, Mathieu Vaillant, Karolina Hankiewicz, C. Bensa, Philippe Cabre, Jérôme De Seze, Aurélie Ruet, Thibault Moreau, Romain Casey, Ivania Patry, Romain Marignier, Abdullatif Al-Khedr, Abir Wahab, Alexis Montcuquet, Chantal Nifle, Jean-Philippe Camdessanché, Guillaume Mathey, David Brassat
Publikováno v:
JAMA neurology
JAMA neurology, American Medical Association, 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA Neurol
JAMA neurology, 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA neurology, American Medical Association (imprimé) / 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA neurology, American Medical Association, 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA Neurol
JAMA neurology, 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
JAMA neurology, American Medical Association (imprimé) / 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
International audience; Importance:Risk of developing progressive multifocal leukoencephalopathy (PML) is the major barrier to using natalizumab for patients with multiple sclerosis (MS). To date, the association of risk stratification with PML incid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb9fe83fce128bcf85d44168fa11c4d3
https://hal.univ-lorraine.fr/hal-02302155
https://hal.univ-lorraine.fr/hal-02302155